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ABSTRACT 
Gastrin controls gastric acid secretion and mucosal cell growth, especially of 
enterochromaffin-like cells, via gastrin/cholecystokinin-2 receptor (CCK2R) binding and 
downstream signalling.  Studies in animal models, healthy subjects and patients with gastric 
neuroendocrine tumours provide compelling evidence to justify developing a CCK2R 
antagonist (CCK2RA) for preventing or treating the trophic effects of hypergastrinaemia or 
conditions expressing CCK2R, and with or without a proton pump inhibitor, for treating 
gastric acid-related conditions.  Many compounds have been studied, but most have had 
problems with potency, selectivity for CCK2 versus CCK1 receptor, solubility or oral 
bioavailability.  None has yet been marketed.  Netazepide and Z-360 are currently undergoing 
clinical development, for treatment of gastric neuroendocrine tumours and pancreatic cancer, 
respectively.  There are several other potential indications for a CCK2RA and an unmet need. 
INTRODUCTION 
Gastrin is a peptide hormone produced by a single gene and synthesised from preprogastrin, 
which is processed into progastrin and amidated gastrin peptide fragments, mostly G17 and 
G34 [1].  All gastrins have a C-terminal amidated tetrapeptide that acts at G protein-coupled 
CCK2R in the stomach and central and peripheral nervous systems.  The C-terminal 
tetrapeptide is identical to that of another peptide hormone, cholecystokinin, which acts 
predominantly at CCK1 receptors in the pancreas, gallbladder and central and peripheral 
nervous systems.   
Food releases gastrin from G cells in the gastric antrum.  Gastrin binds to CCK2R on 
enterochromaffin-like (ECL) cells in the oxyntic mucosa causing them to synthesise and 
secrete histamine, which in turn stimulates adjacent parietal cells to secrete acid.  Acid 
secretion is mediated by the proton pump on parietal cells via histamine H2- and 
muscarinic M3-receptors (Figure 1).  Gastrin also induces proliferation, migration, 
differentiation and anti-apoptosis of gastric epithelial cells; regulates various genes in the 
gastric mucosa; and stimulates paracrine cascades, including cytokines and growth factors 
[2].   
In this article, we describe the potential therapeutic uses of a CCK2RA.  We cite evidence 
from animal models, healthy subjects, and patients. 
  
TYPES OF CCK2RA  
The discovery that asperlicin, a benzodiazepine-related natural product, had weak affinity for 
CCK1 receptors led to invention of various benzodiazepine-derived CCK2RA, such as  
L-36,718 (devazepide), L-365,260, CI-988, YM022, Z-360 and YF476 (netazepide), and to 
other classes of CCK2RA [3].  Two new classes have recently been invented: JB95008 is a 
substituted imidazole [4] and JNJ-26070109 is a benzamide derivative [5].  Most CCK2RA 
have had problems with potency, selectivity for the CCK2 versus CCK1 receptor, solubility or 
oral bioavailability.  No CCK2RA has yet been developed into a medicine. 
CCK2RA STUDIES IN ANIMAL MODELS  
CCK2RA have been tested in many types of animal model.  JNJ-26070109 [5] and netazepide 
[6] caused dose-dependent inhibition of pentagastrin-stimulated acid secretion in rats and 
dogs.  Netazepide prevented the increases in ECL-cell activity and density, oxyntic mucosal 
thickness, mucosal histamine decarboxylase (HDC) activity and serum pancreastatin caused 
by proton pump inhibitor (PPI) induced hypergastrinaemia in rats [7].  Pancreastatin is 
derived from chromogranin A (CgA), an ECL-cell biomarker.  Netazepide not only prevented 
formation of ECL-cell derived gastric carcinoids accelerated by hypergastrinaemia induced 
by loxtidine, an insurmountable histamine H2-receptor antagonist (H2RA), in Mastomys 
rodents, but also caused regression of formed lesions [8].  Netazepide and loxtidine had 
synergistic inhibitory effects on gastric atrophy and cancer in H. felis infected transgenic 
hypergastrinaemic INS-GAS mice, whereas a PPI had no effect [9].  Netazepide also 
prevented: the inflammatory response of the gastric mucosa to H. pylori infection in 
Mongolian gerbils [10**]; hypergastrinaemia-induced lesions in mice similar to those 
observed in patients with Barrett’s oesophagus [11,12]; and NSAID-induced gastric ulcers in 
rats as effectively as omeprazole [13].  YM022 [14] and JNJ-26070109 [5] prevented rebound 
hyper-responsiveness of acid secretion to pentagastrin after stopping omeprazole in rats.  Co-
administration of a CCK2RA with an opioid improved anti-nociception and opioid tolerance 
in animal pain models [15]. 
CCK2RA STUDIES IN HEALTHY SUBJECTS 
There have been few studies of the clinical pharmacology of CCK2RA in healthy subjects.   
L-365,260 produced modest and short lasting inhibition of gastrin-stimulated acid secretion 
[16].  CI-988 had some effect on CCK4-induced panic symptoms [17].  Single oral doses of 
netazepide caused dose-dependent increases in basal and food-stimulated gastric pH for more 
than 24h [18], and dose-dependent inhibition of pentagastrin-induced gastric acid secretion 
  
[19].  Repeated oral doses of netazepide caused persistent inhibition of pentagastrin-induced 
acid secretion [19,20**], and prevented the increase in plasma CgA resulting from 
rabeprazole-induced hypergastrinaemia [20**].  Netazepide suppressed acid production as 
effectively as rabeprazole, and the combination suppressed it more than either treatment alone 
[20**].  A spray-dried formulation of netazepide had linear pharmacokinetics and oral 
bioavailability of 15% [18].  By comparison, bioavailability in rat and dog was 25–50% [6].  
POTENTIAL CLINICAL INDICATIONS FOR A CCK2RA 
Thus, animal models and healthy volunteer studies provide compelling evidence for 
developing a CCK2RA for clinical use.  Potential indications are: hypergastrinaemia; acid-
related conditions; H. pylori infection; and conditions where CCK2R are overexpressed 
(Figure 2).  However, to date there have been very few studies in patients.   
HYPERGASTRINAEMIA-ASSOCIATED CONDITIONS 
There are several causes of hypergastrinaemia, with possible consequences that may be 
treatable by a CCK2RA. 
1.  Chronic atrophic gastritis (CAG) and Zollinger-Ellison syndrome (ZES)  
CAG- and ZES hypergastrinaemia can lead to ECL-cell hyperplasia and in some cases gastric 
neuroendocrine tumours (NETs), called types 1 and 2, respectively [21].  Gastric NETs are 
rare [22], but have the potential to metastasise [21].   
Netazepide once daily for 12 weeks reduced the number of tumours and size of the largest 
one and normalised circulating CgA in 16 patients with CAG, achlorhydria, 
hypergastrinaemia and multiple gastric NETs, [23,24**].  After 12weeks off treatment, the 
number of tumours and size of the largest one remained unchanged but  CgA increased again.  
Netazepide reduced mRNA abundances of CgA and HDC [24**] and reduced miR-222, 
which was over-expressed, in mucosal biopsies [25**].  miR-222 targets the tumour 
suppressor and oncogene p27
kip1
 (Figure 3).  Serum gastrin did not increase further on 
netazepide, confirming patients had achlorhydria.  Netazepide was safe and well tolerated.  
Guidelines recommend regular endoscopic surveillance and mapping and biopsy of type 1 
and 2 NETs, and if there are concerns, polypectomy to remove the tumours or 
antrectomy/gastrinoma resection to remove the source of hypergastrinaemia [21].  However, 
tumours often regrow after polypectomy, and antrectomy carries the risk of morbidity and 
mortality and isn’t always successful.  A CCK2RA is a potential alternative treatment for 
type 1 NETs, which are gastrin driven and comprise 80% of gastric NETs.  Treatment should 
  
probably be continuous otherwise tumours may regrow, even if eradicated.  Progress can be 
monitored by CgA in blood or biomarkers in biopsies.  Patients with pernicious anaemia (PA) 
also have a seven-fold increased risk of developing gastric adenocarcinoma [26].  A CCK2RA 
might also help prevent gastric NETs and adenocarcinoma in PA patients.  The acid 
suppressant and anti-trophic effects of a CCK2RA also make it an ideal potential treatment for 
ZES patients with type 2 NETs.  No trial has been reported.   
2.  PPI-induced hypergastrinaemia 
Although PPIs are safe medicines, PPI-induced hypergastrinaemia has been reported to cause: 
ECL- and parietal-cell hyperplasia; fundic gland polyps; increased risk of bone fractures; 
rebound hyperacidity and dyspepsia after PPI withdrawal; and malignant ECL-cell tumours in 
case reports.  A CCK2RA should be free of those unwanted effects, and should prevent them 
if co-administered with a PPI. 
(a).  ECL-cell hyperplasia 
In 1,920 patients from 16 studies of patients on long-term PPI therapy, mean gastrin 
concentrations increased by one to three times upper limit of normal, and ECL-cell 
hyperplasia increased by 8–52% [27].  There was no evidence of neoplasia in gastric biopsies, 
and no patient had gastric NETs or adenocarcinoma.  H. pylori positive patients had a much 
higher risk of ECL-cell hyperplasia and corpus atrophy.  There have been isolated case 
reports of gastric NETs [28] and gastric cancer [29] in patients with long-term PPI-induced 
hypergastrinaemia.  A CCK2RA does not cause ECL-cell hyperplasia and prevents PPI-
induced ECL-cell hyperplasia in healthy subjects [20**].   
(b).  Fundic gland polyps 
Long-term PPI therapy is associated with increased risk of fundic gland polyps [30*], so they 
merit a trial of co-administered CCK2RA. 
(c).  Bone fractures 
Long-term PPI therapy also increases the risk of bone fractures [31].  An effect of PPI-
induced hypergastrinaemia on the vacuolar type H
+
-ATPase on osteoclasts that mediates 
acidification of intracellular organelles is a possible cause.  Bone fracture risk is also 
increased in PA patients [32], and osteoporosis risk is increased in CAG patients [33], which 
excludes a direct effect of PPI on bone, because PA and CAG patients both have hypoacidity 
and secondary hypergastrinaemia.   
H
+
/K
+
-ATPase -subunit knock-out mice with hypergastrinaemia developed bone loss and 
deterioration of bone quality, which was partly prevented by netazepide [34].  Netazepide 
  
caused hypoacidity and hypergastrinaemia in control animals, as expected, but no bone 
changes, suggesting hypergastrinaemia rather than hypoacidity is the mechanism.  Thus, 
CCK2RA co-administration might reduce the risk of fracture in PPI-treated patients.   
(d).  Rebound hyperacidity  
Rebound hyperacidity and dyspepsia have been reported after PPI withdrawal [35]. 
Netazepide did not cause rebound hyperacidity [20**] and would prevent it should it occur 
after PPI withdrawal.   
3.  Mutations in KCNQ1, KCN1E and ATP4A genes 
Patients with the rare Jervell and Lange-Nielsen syndrome have hypergastrinaemia secondary 
to hypochlorhydria caused by mutations of KCNQ1 or KCNE1 genes, which are essential for 
acid secretion.  Some patients develop ECL-cell tumours and gastric cancer [36*].  Patients 
with ATP4A gene mutation, which encodes the α-subunit of the proton pump, also have 
hypergastrinaemia and develop gastric NETs and adenocarcinoma [37*].  Such patients merit 
a CCK2RA trial. 
4.  Cysteamine therapy for cystinosis 
Cysteamine slows progression of cystinosis, by removing cystine from cells, but it increases 
serum gastrin and gastric acid, and is ulcerogenic.  Some patients require PPI therapy [38].  A 
CCK2RA, with or without a PPI, is a potential therapy. 
ACID-RELATED CONDITIONS 
CCK2RA should be free of the unwanted effects of PPI-induced hypergastrinaemia, and if 
co-administered with a PPI should prevent those unwanted effects, and improve acid control 
[20**].  
H. PYLORI INFECTION 
H. pylori is a risk factor for peptic ulcer disease and gastric cancer.  Netazepide completely 
prevented the inflammatory response of gastric mucosa to H. pylori in Mongolian gerbils 
[10**].  Therefore, a CCK2RA with or without a PPI could be a useful addition to antibiotic 
regimens for H. pylori eradication.  However, this has yet to be tested in patients.   
CONDITIONS ASSOCIATED WITH CCK2R EXPRESSION 
CCK2 receptors are expressed on cells of some patients with pancreatic cancer [39], Barrett’s 
oesophagus [40], gastrointestinal stromal tumours [41], gastric adenocarcinoma [42], and 
other cancers.  Therefore, a CCK2RA may have therapeutic benefit. 
  
1.  Pancreatic adenocarcinoma 
JB95008 prolonged life in a small placebo-controlled trial, but a second trial showed no 
difference between JB95008 and 5-fluorouracil.  Development was stopped because JB95008 
required intravenous infusion due to poor oral bioavailability [4].  In a placebo-controlled 
trial of gemcitabine with or without Z-360, there were no differences between treatments 
[43]. 
2.  Barrett’s oesophagus 
PPI-induced hypergastrinaemia is associated with advanced oesophageal adenocarcinoma in   
patients with Barrett’s oesophagus [44].  CCK2RA co-administration should increase acid 
suppression and inhibit any trophic effect of PPI-induced hypergastrinaemia.  A CCK2RA 
alone might be adequate.  A trial of the effect of netazepide on biomarkers in Barrett’s 
patients is in progress [Abrams J, https://clinicaltrials.gov, NCT01298999].   
3.  Gastrointestinal stromal tumour (GIST) 
GISTs are removed surgically if localised or treated with a tyrosine kinase inhibitor if 
metastatic, but they can ‘escape’.  Gastrin increases tumour volume and cell proliferation and 
stimulates kinase pathways in GIST xenografts, which express CCK2 receptors [41].  A trial 
of a CCK2RA is therefore justified. 
4.  Gastric adenocarcinoma 
Many patients have raised serum gastrin.  Alpha-amidated gastrins and their receptors are 
detectable in 80% [42].  It is not clear whether long-term PPI therapy increases the risk of 
gastric adenocarcinoma [30].  Patients usually present late, so a potential therapeutic effect of 
a CCK2RA seems unlikely. 
CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS 
L-365,260 and CI-988 lacked effect in patients with panic disorder [45].  L-365,260 did not 
augment the analgesic effect of morphine in neuropathic pain [15], but Z-360 may have a role 
in pancreatic cancer pain [43,46]. 
CONCLUSIONS AND FUTURE WORK 
The hormone gastrin regulates several essential biological processes, including gastric acid 
secretion, mucosal remodelling and proliferation via CCK2 receptors.  Hypergastrinaemia 
dysregulates those processes and contributes to development of various diseases.  CCK2RA 
inhibit CCK2R receptor binding and have the potential to reduce pathological downstream 
signalling, particularly of ECL cells.   
  
More is known about the role of gastrin in health and disease [1,2] since the last review in this 
journal [47], and there is further evidence of the malignant potential of hypergastrinaemia 
[36*,37*].  miR-222, which targets the tumour suppressor and oncogene p27
kip1
, is a potential 
biomarker for monitoring gastrin-induced premalignant changes in the stomach.  There is 
increasing evidence of involvement of CCK2R in progression of Barrett’s oesophagus 
[11,12,40,44].   
Only netazepide and Z-360 are currently in clinical development in patients, for treatment of 
type 1 gastric NETs [23,24**] and pancreatic cancer [43,46], respectively.  Ceclazepide 
(TR2-A) is a new benzodiazepine-derived CCK2RA and prodrug that has advantages over 
netazepide in terms of selectivity, solubility and bioavailability, and is in pre-clinical 
development [48]. 
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HIGHLIGHTS 
 Gastrin controls gastric acid secretion and mucosal cell growth via CCK2R. 
 CCK2RA can prevent/treat consequences of hypergastrinaemia or acid-related diseases.   
 CCK2RA can eradicate type 1 NETs and reduce miR-222, which targets p27
kip1
.   
 miR-222 is a potential biomarker for gastrin-induced gastric premalignant changes.  
 There are many other potential clinical indications for a CCK2RA, and an unmet need. 
 
 
  
  
FIGURE LEGENDS 
Figure 1.  Control of gastric acid secretion  
 
Figure 2.  The main causes of hypergastrinaemia, conditions associated with increased 
CCK2R expression, and status of CCK2RA tested in patients. 
1. Netazepide (YF476): Reduced number and size of the largest tumour and normalised 
CgA in patients with type-1 gastric NETs [23,24].  Still in development.   
2. Z-360: No evidence of efficacy when added to gemcitabine, apart from apparent 
reduction in pain, in patients with pancreatic cancer [43].  Still in development. 
3. JB95008: Intravenous infusion prolonged life significantly in patients with pancreatic 
cancer, but no difference when compared with 5-FU [4].   Development stopped 
because of poor oral bioavailability.   
4. L-365,320: No effect in patients with panic disorder [45].  No augmentation of 
analgesic effect of morphine in patients with neuropathic pain [15].  Caused 
arrhythmias; development stopped [3]  
5. Cl-988: No effect in patients with panic disorder [45].  Development stopped [3]. 
 
Figure 3.  A schematic diagram of the signalling pathways that are activated by CCK2R 
binding.  miR-222 transcription is increased via the PKC and PI3K pathways and partially via 
the MAPK pathway.  The pri(mary)-miR-222 transcript is cleaved by the RNAse II enzyme 
Drosha into a hairpin structure (pre-miR-222) which is transported from the nucleus to the 
cytoplasm via exportin-5.  Pre-miR-222 is cleaved by a second RNase II enzyme, Dicer, into 
mature miR-222 which associates with RISC to target imperfect complementary mRNA 
sequences.  Mature miR-222 inhibits the translation of p27
kip1
 which increases cell migration 
and epithelial mesenchymal transition in AGSGR cells. 
Reproduced with permission from [25]  
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1. Netazepide (YF476): Reduced number and size of the largest tumour and normalised 
CgA in patients with type-1 gastric NETs [23,24].  Still in development. 
2. Z-360: No evidence of efficacy when added to gemcitabine, apart from apparent 
reduction in pain, in patients with pancreatic cancer [43].  Still in development.  
3. JB95008: Intravenous infusion prolonged life significantly in patients with pancreatic 
cancer, but no difference when compared with 5-FU [4]. Development stopped because 
of poor oral bioavailability.  
4. L-365,320: No effect in patients with panic disorder [45], no augmentation of analgesic 
effect of morphine in patients with neuropathic pain [15].  Caused arrhythmias; 
development stopped [3].  
5. Cl-988: No effect in patients with panic disorder [45].  Development stopped [3].   
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